417 related articles for article (PubMed ID: 30813468)
1. Role of Histamine H₃ Receptor Antagonists on Intraocular Pressure Reduction in Rabbit Models of Transient Ocular Hypertension and Glaucoma.
Lanzi C; Lucarini L; Durante M; Sgambellone S; Pini A; Catarinicchia S; Łażewska D; Kieć-Kononowicz K; Stark H; Masini E
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30813468
[TBL] [Abstract][Full Text] [Related]
2. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action.
Sharif NA
Curr Drug Targets; 2010 Aug; 11(8):978-93. PubMed ID: 20426763
[TBL] [Abstract][Full Text] [Related]
3. Novel Insight of Histamine and Its Receptor Ligands in Glaucoma and Retina Neuroprotection.
Sgambellone S; Lucarini L; Lanzi C; Masini E
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439851
[TBL] [Abstract][Full Text] [Related]
4. NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGFβ2-Induced Outflow in HTM/HSC Constructs.
Bastia E; Toris CB; Brambilla S; Galli C; Almirante N; Bergamini MVW; Masini E; Sgambellone S; Unser AM; Ahmed F; Torrejon KY; Navratil T; Impagnatiello F
Invest Ophthalmol Vis Sci; 2021 Mar; 62(3):17. PubMed ID: 33704360
[TBL] [Abstract][Full Text] [Related]
5. Intraocular pressure-lowering effects of imidazo[1,2-a]- and pyrimido[1,2-a]benzimidazole compounds in rats with dexamethasone-induced ocular hypertension.
Marcus AJ; Iezhitsa I; Agarwal R; Vassiliev P; Spasov A; Zhukovskaya O; Anisimova V; Ismail NM
Eur J Pharmacol; 2019 May; 850():75-87. PubMed ID: 30716317
[TBL] [Abstract][Full Text] [Related]
6. Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial.
Oddone F; Rossetti L; Tanga L; Berardo F; Ferrazza M; Michelessi M; Roberti G; Manni G; Centofanti M
PLoS One; 2015; 10(10):e0140601. PubMed ID: 26484767
[TBL] [Abstract][Full Text] [Related]
7. Effects of a non-selective beta-blocker on adult rat anterograde axonal transport and retinal ganglion layer after increased intraocular pressure.
Díaz F; Villena A; Moreno M; Vidal L; Parrado C; García-Campos J; de Vargas IP
Histol Histopathol; 2005 Oct; 20(4):1077-84. PubMed ID: 16136490
[TBL] [Abstract][Full Text] [Related]
8. Nanoencapsulated hybrid compound SA-2 with long-lasting intraocular pressure-lowering activity in rodent eyes.
Stankowska DL; Millar JC; Kodati B; Behera S; Chaphalkar RM; Nguyen T; Nguyen KT; Krishnamoorthy RR; Ellis DZ; Acharya S
Mol Vis; 2021; 27():37-49. PubMed ID: 33633438
[TBL] [Abstract][Full Text] [Related]
9. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
[TBL] [Abstract][Full Text] [Related]
10. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
Sonty S; Mundorf TK; Stewart JA; Stewart WC
Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
[TBL] [Abstract][Full Text] [Related]
11. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
[TBL] [Abstract][Full Text] [Related]
12. Topical administration of rapamycin promotes retinal ganglion cell survival and reduces intraocular pressure in a rat glaucoma model.
Wang F; Ma F; Song Y; Li N; Li X; Pang Y; Hu P; Shao A; Deng C; Zhang X
Eur J Pharmacol; 2020 Oct; 884():173369. PubMed ID: 32712092
[TBL] [Abstract][Full Text] [Related]
13. Time-dependent retinal ganglion cell loss, microglial activation and blood-retina-barrier tightness in an acute model of ocular hypertension.
Trost A; Motloch K; Bruckner D; Schroedl F; Bogner B; Kaser-Eichberger A; Runge C; Strohmaier C; Klein B; Aigner L; Reitsamer HA
Exp Eye Res; 2015 Jul; 136():59-71. PubMed ID: 26001526
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial.
Koz OG; Ozsoy A; Yarangumeli A; Kose SK; Kural G
Acta Ophthalmol Scand; 2007 Dec; 85(8):838-43. PubMed ID: 17680841
[TBL] [Abstract][Full Text] [Related]
15. Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric Oxide-Donating Bimatoprost in Preclinical Models.
Impagnatiello F; Toris CB; Batugo M; Prasanna G; Borghi V; Bastia E; Ongini E; Krauss AH
Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6558-64. PubMed ID: 26457541
[TBL] [Abstract][Full Text] [Related]
16. The effect of topical CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure and aqueous humor dynamics in rabbits.
Inoue T; Yokoyoma T; Mori Y; Sasaki Y; Hosokawa T; Yanagisawa H; Koike H
Curr Eye Res; 2001 Aug; 23(2):133-8. PubMed ID: 11840352
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the cysteinyl leukotriene pathways increases survival of RGCs and reduces microglial activation in ocular hypertension.
Trost A; Motloch K; Koller A; Bruckner D; Runge C; Schroedl F; Bogner B; Kaser-Eichberger A; Strohmaier C; Ladek AM; Preishuber-Pfluegl J; Brunner SM; Aigner L; Reitsamer HA
Exp Eye Res; 2021 Dec; 213():108806. PubMed ID: 34715090
[TBL] [Abstract][Full Text] [Related]
18. Use of a Bayesian network to predict the nighttime intraocular pressure peak from daytime measurements.
Nordmann JP; Berdeaux G
Clin Ther; 2007 Aug; 29(8):1751-60; discussion 1750. PubMed ID: 17919556
[TBL] [Abstract][Full Text] [Related]
19. Functional and structural evaluation of lamotrigine treatment in rat models of acute and chronic ocular hypertension.
Sandalon S; Könnecke B; Levkovitch-Verbin H; Simons M; Hein K; Sättler MB; Bähr M; Ofri R
Exp Eye Res; 2013 Oct; 115():47-56. PubMed ID: 23810807
[TBL] [Abstract][Full Text] [Related]
20. Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes.
Sharif NA; McLaughlin MA; Kelly CR; Katoli P; Drace C; Husain S; Crosson C; Toris C; Zhan GL; Camras C
Exp Eye Res; 2009 Mar; 88(3):386-97. PubMed ID: 18992242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
